Microbiome Modulator

Bifidobacterium breve

Bifidobacterium breve

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

10-20 billion CFU/day. The B-3 body composition trials used 20 billion CFU/day. General probiotic dosing for adults typically falls in the 5-20 billion CFU/day range.

watchEffect Window

Body composition changes in the B-3 trials became significant around weeks 8-12. Gut colonization and microbiome shifts may begin within 1-2 weeks but clinically meaningful effects require sustained use.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Bifidobacterium breve is an early-life commensal with preliminary, strain-specific evidence for adult body composition, skin, and gut-barrier applications.

B. breve is a well-characterized commensal bacterium that dominates the infant gut and persists at lower levels in adults. The strongest supplement-relevant evidence comes from two small RCTs of the B-3 strain showing modest body-fat effects in overweight adults over 12 weeks. Adult evidence also now includes a negative-but-reassuring 6-week safety trial of the Bif195 strain under an exercise-induced intestinal-permeability challenge and a manufacturer-funded skin-imaging trial of M-16V. Neonatal M-16V data remain clinically interesting but are not the same thing as consumer supplement evidence. Strain specificity matters here more than for many probiotics, and the overall adult evidence base is still preliminary.

B. breve colonizes the gut and produces acetate and lactate through carbohydrate fermentation. Acetate cross-feeds butyrate-producing bacteria, supporting broader microbial community health. B. breve modulates Th1/Th2 immune balance, strengthens epithelial barrier integrity through tight junction protein upregulation, and some strains produce conjugated linoleic acid. The B-3 strain may influence lipid metabolism and adiposity through gut-derived metabolic signaling pathways that are not yet fully characterized.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Modest body fat reduction in overweight adults (B-3 strain, 20 billion CFU/day, 12 weeks)
  • Prevention of visceral fat accumulation in pre-obese adults (B-3 strain)

Secondary Outcomes

  • General gut microbiome support through acetate production and Bifidobacterium colonization
  • Potential immune modulation through Th1/Th2 balance calibration

Safety

Contraindications and Interactions

Contraindications

  • Critical illness or ICU admission
  • Severe immunocompromise
  • Known allergy to product excipients

Side effects

  • Mild gas or bloating
  • Transient change in stool consistency

Interactions

  • Antibiotics (antibacterial)

Avoid if

  • Critically ill or in an ICU setting
  • Severely immunocompromised without physician guidance
  • Unable to identify the specific B. breve strain in the product

Evidence

Study-level References

bbreve-SRC-001Randomized, double-blind, placebo-controlled trial
Sourceopen_in_new

Minami J, Kondo S, Yanagisawa N, et al. Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial. Biosci Microbiota Food Health. 2018;37(3):67-75.

Population: Healthy pre-obese Japanese adults (BMI 25-30) aged 20-64 years

Dose protocol: 20 billion CFU/day B. breve B-3 capsules for 12 weeks in pre-obese Japanese adults (BMI 25-30).

Key findings: Significantly lower body fat mass and percent body fat in the B-3 group vs placebo. Placebo group experienced visceral fat area increase that did not occur in B-3 group.

Notes: First well-designed RCT for B-3 on body composition. Small sample (n=80), manufacturer-funded, author conflicts.

Paper content

Key trial demonstrating that the specific B. breve B-3 strain may influence body composition in pre-obese adults. Over 12 weeks, participants taking 20 billion CFU/day of B-3 showed significantly lower body fat mass and body fat percentage compared to placebo. Notably, the placebo group experienced a significant increase in visceral fat area over the study period while the B-3 group did not. The effect sizes were modest and the sample size was relatively small (n=80). The study used ANCOVA adjusted for baseline values, which is appropriate but the results should be interpreted cautiously given the single-center design and modest participant numbers. This is the first well-designed RCT for B-3 specifically on body composition endpoints in adults, building on earlier preliminary work by the same group (Minami et al. 2015, PMID 26090097). The findings suggest a potential role in weight management but require replication in larger and more diverse populations.

bbreve-SRC-002Randomized, double-blind, placebo-controlled trial
Sourceopen_in_new

Sung HK, Kim YI, Lee H, et al. Body Fat Reduction Effect of Bifidobacterium breve B-3: A Randomized, Double-Blind, Placebo Comparative Clinical Trial. Nutrients. 2023;15(1):28.

Population: Healthy overweight Korean adults

Dose protocol: B. breve B-3 capsules for 12 weeks in overweight Korean adults, with DEXA-based body composition assessment.

Key findings: Lower body weight vs baseline and reduced waist and hip circumference vs placebo at 12 weeks. Provides cross-population replication with more objective measurement.

Notes: Replication study using DEXA. Generated a published methodological critique (PMID 36904094) and author response.

Paper content

Replication study of the B. breve B-3 body composition effect, this time in a Korean population using DEXA for objective body fat measurement. The trial found that B-3 supplementation led to lower body weight compared to baseline and reduced waist and hip circumference compared to placebo at 12 weeks. This study is notable because it uses a more rigorous body composition endpoint (DEXA) than the earlier Minami 2018 trial and was conducted in a different ethnic population, providing some cross-population replication support. However, the study generated a published commentary (Lee 2023, PMID 36904094) raising methodological questions, and the authors published a response addressing those concerns. The overall body of B-3 evidence for body composition remains at a preliminary stage with small trials, manufacturer involvement in funding, and modest effect sizes across studies.

bbreve-SRC-003Strain-specific systematic review with meta-analysis of RCTs and non-RCTs
Sourceopen_in_new

Athalye-Jape G, Rao S, Simmer K, Patole S. Bifidobacterium breve M-16V as a Probiotic for Preterm Infants: A Strain-Specific Systematic Review. JPEN J Parenter Enteral Nutr. 2018;42(4):677-688.

Population: Preterm infants from 5 RCTs (n=482) and 4 non-RCTs (n=2,496)

Dose protocol: Systematic review of B. breve M-16V in preterm infants, pooling 5 RCTs (n=482) and 4 non-RCTs (n=2,496).

Key findings: RCT meta-analysis found no significant benefit on NEC, sepsis, or mortality. Non-RCT meta-analysis showed significant benefits on sepsis, mortality, and time to full feeds. No adverse events reported.

Notes: Important for characterizing the strain-specific evidence landscape. Clinical context only, not consumer supplement relevant.

Paper content

First strain-specific systematic review of Bifidobacterium breve M-16V in preterm infants. The meta-analysis of 5 RCTs (n=482) found no statistically significant benefits on NEC, late-onset sepsis, mortality, or time to full feeds. However, the non-RCT evidence (n=2,496) showed significant benefits on sepsis, mortality, and feeding advancement. Four of the five RCTs carried high or unclear risk of bias in multiple domains, limiting the strength of conclusions from randomized data alone. No adverse effects from B. breve M-16V were reported in any included study. The review highlights that randomized evidence for this specific strain in preterm infants remains underpowered and that adequately powered cluster RCTs are needed. This is an important reference because it demonstrates the gap between observational promise and randomized confirmation for probiotic use in vulnerable neonatal populations.

bbreve-SRC-004Randomized, double-blind, placebo-controlled trial
Sourceopen_in_new

Nishikawa Y, Xu C, Yoshimoto S, Katsumata N, Iwabuchi N, Yanagisawa N, Koido S, Tanaka M, Xiao JZ, Asaoka D, Ohkusa T, Sato N. Imaging and Microorganism Analyses of the Effects of Oral Bifidobacterium breve Intake on Facial Skin in Females: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2025;17(18):2976. doi:10.3390/nu17182976. PMID:41010502.

Population: Healthy women aged 30 years and older with no major skin conditions.

Dose protocol: B. breve M-16V 2 x 10^10 CFU/day for 12 weeks in 120 healthy women aged 30+.

Key findings: Improved brown spot and pore scores on VISIA facial imaging versus placebo. Placebo group showed progressive skin deterioration that was suppressed by the probiotic.

Notes: First RCT connecting oral B. breve M-16V to skin outcomes in adults. Manufacturer-funded (Morinaga). Extends M-16V evidence beyond neonatal settings.

Paper content

This 12-week RCT in 120 healthy women found that oral Bifidobacterium breve M-16V at 2 x 10^10 CFU/day significantly improved brown spot and pore scores on VISIA facial imaging compared to placebo. The placebo group showed progressive skin deterioration over the study period that was suppressed in the probiotic group. Skin and gut microbiota shifts were also observed, supporting a gut-skin axis mechanism for the probiotic's dermatologic effects.

bbreve-SRC-005Randomized, double-blind, placebo-controlled, parallel-group trial
Sourceopen_in_new

Engel S, Mortensen B, Wellejus A, Vera-Jimenez N, Struve C, Brummer RJ, Damholt A, Woods T, Shanahan F. Safety of Bifidobacterium breve, Bif195, employing a human exercise-induced intestinal permeability model: a randomised, double-blinded, placebo-controlled, parallel group trial. Benef Microbes. 2022;13(3):243-252. doi:10.3920/BM2021.0173. PMID:35866597.

Population: Healthy trained adults exposed to an exercise-induced intestinal-permeability challenge.

Dose protocol: B. breve Bif195 for 6 weeks in 126 healthy trained adults undergoing a treadmill-induced intestinal-permeability challenge.

Key findings: No significant benefit on lactulose/rhamnose ratio, I-FABP, GI symptoms, cytokines, or adverse events versus placebo. Supports tolerability rather than efficacy for gut-permeability endpoints.

Notes: Helpful negative study because it narrows overbroad gut-barrier marketing and supports short-term safety in a stress-test model.

Paper content

This 6-week randomized, double-blind, placebo-controlled trial tested Bifidobacterium breve Bif195 in 126 healthy trained adults using a treadmill-based intestinal-permeability challenge. The exercise model worked, doubling the lactulose/rhamnose ratio and increasing cytokines after the challenge, but Bif195 did not improve permeability, I-FABP, GI symptoms, or safety labs versus placebo. That makes the trial useful mostly as a boundary-setting study: it supports short-term tolerability of Bif195 in a physiologic stress model, but it does not support marketing the strain as a proven gut-barrier intervention in healthy adults.

Guides

Setup

Help